OPEN END TURBO OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 14:09:45 08/07/2024 BST | ||
| 5.4 EUR / 5.7 EUR | +2.40% |
|
| Current month | -4.75% | ||
| 1 month | +20.18% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 08/07/24 | 5.24 | -3.32% |
| 05/07/24 | 5.42 | -3.90% |
| 04/07/24 | 5.64 | -1.40% |
| 03/07/24 | 5.72 | +6.32% |
| 02/07/24 | 5.38 | -4.27% |
Delayed Quote Börse Stuttgart
Last update July 08, 2024 at 10:17 am
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JB4JAB |
| ISIN | DE000JB4JAB8 |
| Date issued | 16/10/2023 |
| Strike | 531.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 15.63 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 17.33 € |
|---|---|
| Lowest since issue | 4.27 € |
| Spread | 0.3 € |
| Spread % | 5.25% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
474.6
USD
Average target price
468.3
USD
Spread / Average Target
-1.33%
- Stock Market
- Certificates
- Certificat
